Nothing Special   »   [go: up one dir, main page]

SG11201703148TA - Aadc polynucleotides for the treatment of parkinson's disease - Google Patents

Aadc polynucleotides for the treatment of parkinson's disease

Info

Publication number
SG11201703148TA
SG11201703148TA SG11201703148TA SG11201703148TA SG11201703148TA SG 11201703148T A SG11201703148T A SG 11201703148TA SG 11201703148T A SG11201703148T A SG 11201703148TA SG 11201703148T A SG11201703148T A SG 11201703148TA SG 11201703148T A SG11201703148T A SG 11201703148TA
Authority
SG
Singapore
Prior art keywords
parkinson
disease
treatment
aadc polynucleotides
aadc
Prior art date
Application number
SG11201703148TA
Inventor
Robert Kotin
Adrian Philip Kells
Bernard Ravina
Original Assignee
Voyager Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voyager Therapeutics Inc filed Critical Voyager Therapeutics Inc
Publication of SG11201703148TA publication Critical patent/SG11201703148TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01028—Aromatic-L-amino-acid decarboxylase (4.1.1.28), i.e. tryptophane-decarboxylase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201703148TA 2014-11-05 2015-11-05 Aadc polynucleotides for the treatment of parkinson's disease SG11201703148TA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462075298P 2014-11-05 2014-11-05
US201562155692P 2015-05-01 2015-05-01
US201562199578P 2015-07-31 2015-07-31
US201562243537P 2015-10-19 2015-10-19
PCT/US2015/059201 WO2016073693A2 (en) 2014-11-05 2015-11-05 Aadc polynucleotides for the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
SG11201703148TA true SG11201703148TA (en) 2017-05-30

Family

ID=55910029

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201703148TA SG11201703148TA (en) 2014-11-05 2015-11-05 Aadc polynucleotides for the treatment of parkinson's disease
SG10202007103TA SG10202007103TA (en) 2014-11-05 2015-11-05 Aadc polynucleotides for the treatment of parkinson's disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202007103TA SG10202007103TA (en) 2014-11-05 2015-11-05 Aadc polynucleotides for the treatment of parkinson's disease

Country Status (14)

Country Link
US (6) US10335466B2 (en)
EP (1) EP3215191B1 (en)
JP (4) JP6401871B2 (en)
KR (1) KR20170096998A (en)
CN (2) CN112553229A (en)
AU (2) AU2015343037B2 (en)
BR (1) BR112017009497A2 (en)
CA (1) CA2966620A1 (en)
HK (1) HK1243922A1 (en)
IL (2) IL251787B (en)
MX (1) MX2017005834A (en)
RU (2) RU2020109343A (en)
SG (2) SG11201703148TA (en)
WO (1) WO2016073693A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
AU2015346164B2 (en) 2014-11-14 2020-01-30 Voyager Therapeutics, Inc. Modulatory polynucleotides
CA2970730A1 (en) * 2015-01-16 2016-07-21 Voyager Therapeutics, Inc. Central nervous system targeting polynucleotides
WO2017096162A1 (en) 2015-12-02 2017-06-08 Voyager Therapeutics, Inc. Assays for the detection of aav neutralizing antibodies
JP7220080B2 (en) 2016-05-18 2023-02-09 ボイジャー セラピューティクス インコーポレイテッド Compositions and methods for treating Huntington's disease
SG11201809699XA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Modulatory polynucleotides
CN110650673B (en) 2016-08-30 2024-04-09 加利福尼亚大学董事会 Methods for biomedical targeting and delivery and devices and systems for practicing the methods
EP3519431A1 (en) 2016-09-28 2019-08-07 Cohbar Inc. Therapeutic mots-c related peptides
US11117930B2 (en) 2017-02-23 2021-09-14 Adrx, Inc. Peptide inhibitors of transcription factor aggregation
EA201992001A1 (en) 2017-03-17 2020-01-24 Адверум Байотекнолоджис, Инк. COMPOSITIONS AND METHODS FOR INCREASING GENE EXPRESSION
CA3059891A1 (en) 2017-04-14 2018-10-18 National Taiwan University Gene therapy for aadc deficiency
CA3061368A1 (en) * 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
EP3634978A1 (en) 2017-06-07 2020-04-15 Adrx, Inc. Tau aggregation inhibitors
JOP20190269A1 (en) 2017-06-15 2019-11-20 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
WO2019070891A1 (en) * 2017-10-03 2019-04-11 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
JP2021521852A (en) * 2018-04-27 2021-08-30 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． How to measure the potency of AADC viral vector
KR20210019996A (en) * 2018-05-15 2021-02-23 보이저 테라퓨틱스, 인크. Composition and method for the treatment of Parkinson's disease
WO2019222441A1 (en) * 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
US12060567B2 (en) 2018-06-13 2024-08-13 Voyager Therapeutics, Inc. Engineered untranslated regions (UTR) for AAV production
CN108795946B (en) * 2018-06-28 2022-03-04 北京锦篮基因科技有限公司 Recombinant adeno-associated virus carrying SMN1 gene expression cassette and application thereof
AU2019310459A1 (en) 2018-07-24 2021-02-18 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
CN113383010A (en) * 2018-09-28 2021-09-10 沃雅戈治疗公司 Ataxin expression constructs with engineered promoters and methods of use thereof
US20210348242A1 (en) 2018-10-04 2021-11-11 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
SG11202103425YA (en) 2018-10-05 2021-05-28 Voyager Therapeutics Inc Engineered nucleic acid constructs encoding aav production proteins
EP3867389A1 (en) 2018-10-15 2021-08-25 Voyager Therapeutics, Inc. Expression vectors for large-scale production of raav in the baculovirus/sf9 system
CN113631225A (en) 2019-01-18 2021-11-09 沃雅戈治疗公司 Methods and systems for producing AAV particles
WO2020160003A1 (en) 2019-01-28 2020-08-06 Cohbar, Inc. Therapeutic peptides
CN113924115A (en) 2019-01-31 2022-01-11 俄勒冈健康与科学大学 Methods for AAV capsids using transcription-dependent directed evolution
US20220243225A1 (en) 2019-04-29 2022-08-04 Voyager Therapeutics, Inc. SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
WO2021030125A1 (en) 2019-08-09 2021-02-18 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
TW202122582A (en) 2019-08-26 2021-06-16 美商航海家醫療公司 Controlled expression of viral proteins
CN115135347A (en) * 2019-12-12 2022-09-30 梅里特斯英国第二有限公司 Methods of treating Parkinson's disease
RU2742837C1 (en) * 2020-06-02 2021-02-11 Общество С Ограниченной Ответственностью "Анабион" Codon-optimized nucleic acid which encodes smn1 protein, and use thereof
EP4192514A1 (en) 2020-08-06 2023-06-14 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
EP3982378A1 (en) 2020-10-09 2022-04-13 Koninklijke Philips N.V. Cryogen-free superconducting magnet system
EP4301768A2 (en) 2021-03-03 2024-01-10 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240141378A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
BR112023016873A2 (en) * 2021-03-12 2023-10-03 Kolon Life Science Inc COMPOSITION TO PREVENT OR TREAT DEGENERATIVE BRAIN DISEASES
EP4313016A1 (en) * 2021-03-29 2024-02-07 Sanford Health Methods and compositions for treating lysosomal storage disorders
WO2023279078A1 (en) * 2021-07-01 2023-01-05 Northwestern University Enhanced expression of an aromatic amino acid decarboxylase (aadc) in the substantia nigra for the treatment of parkinson's disease
WO2023056399A1 (en) 2021-10-02 2023-04-06 The Trustees Of The University Of Pennsylvania Novel aav capsids and compositions containing same
EP4442830A1 (en) * 2021-11-29 2024-10-09 Shanghai Regenelead Therapies Co., Ltd. Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease
WO2023202637A1 (en) * 2022-04-19 2023-10-26 Shanghai Vitalgen Biopharma Co., Ltd. Recombinant aav vectors for treating neurodegenerative disorders
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins
CN118252953A (en) * 2022-12-26 2024-06-28 科辉智药(深圳)新药研究中心有限公司 Gene sequence construct for treating neurodegenerative diseases and application thereof

Family Cites Families (457)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2640638B1 (en) 1988-12-20 1991-02-15 Commissariat Energie Atomique BIOREACTOR AND DEVICE FOR THE CULTURE OF ANIMAL CELLS
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
GB9027917D0 (en) * 1990-12-21 1991-02-13 Ici Plc Expression systems
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5693531A (en) 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
WO1995028493A1 (en) 1994-04-13 1995-10-26 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US20020159979A1 (en) 1994-06-06 2002-10-31 Children's Hospital, Inc. Adeno-associated virus materials and methods
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US5652224A (en) 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5741657A (en) 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
US5756283A (en) 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5688676A (en) 1995-06-07 1997-11-18 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6676935B2 (en) 1995-06-27 2004-01-13 Cell Genesys, Inc. Tissue specific adenoviral vectors
US6197293B1 (en) 1997-03-03 2001-03-06 Calydon, Inc. Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
AU722196B2 (en) 1995-08-30 2000-07-27 Genzyme Corporation Chromatographic purification of adenovirus and AAV
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
US5846528A (en) 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US5962313A (en) 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US5952221A (en) 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
US7026468B2 (en) 1996-07-19 2006-04-11 Valentis, Inc. Process and equipment for plasmid purification
US5866552A (en) 1996-09-06 1999-02-02 The Trustees Of The University Of Pennsylvania Method for expressing a gene in the absence of an immune response
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
AU723497C (en) 1996-09-06 2001-10-11 Trustees Of The University Of Pennsylvania, The Method for recombinant adeno-associated virus-directed gene therapy
AU722375B2 (en) 1996-09-06 2000-08-03 Trustees Of The University Of Pennsylvania, The Methods using cre-lox for production of recombinant adeno-associated viruses
IL128780A0 (en) 1996-09-06 2000-01-31 Univ Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
US20020037867A1 (en) 1999-02-26 2002-03-28 James M. Wilson Method for recombinant adeno-associated virus-directed gene therapy
EP0932694A2 (en) 1996-09-11 1999-08-04 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Aav4 vector and uses thereof
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
CA2272820C (en) 1996-11-20 2012-09-11 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
EP0950091A2 (en) 1996-12-18 1999-10-20 Targeted Genetics Corporation Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6710036B2 (en) 1997-07-25 2004-03-23 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
US6251677B1 (en) 1997-08-25 2001-06-26 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
AU9319198A (en) 1997-09-19 1999-04-05 Trustees Of The University Of Pennsylvania, The Methods and vector constructs useful for production of recombinant aav
EP1015619A1 (en) 1997-09-19 2000-07-05 The Trustees Of The University Of Pennsylvania Methods and cell line useful for production of recombinant adeno-associated viruses
CA2304131A1 (en) 1997-09-19 1999-04-01 James M. Wilson Method for gene transfer using bcl2 and compositions useful therein
US6642051B1 (en) 1997-10-21 2003-11-04 Targeted Genetics Corporation Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
IT1297074B1 (en) 1997-11-21 1999-08-03 Angeletti P Ist Richerche Bio HORMONE-DEPENDENT FORMS OF THE REP PROTEIN OF THE ADENUS ASSOCIATED VIRUS (AAV-2), DNA SEQUENCES CODING FOR THEM, VECTORS THAT
JP2001526900A (en) 1997-12-23 2001-12-25 イントロヘーネ ベスローテン フェンノートシャップ Adeno-associated virus and chimeric adenovirus recombinant virus useful for integrating foreign gene information into chromosomal DNA of target cells
US6410300B1 (en) 1998-01-12 2002-06-25 The University Of North Carolina At Chapel Hill Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
AU2882899A (en) 1998-02-26 1999-09-15 Trustees Of The University Of Pennsylvania, The Stable protection from dystrophic sarcolemmal degeneration and restoration of the sarcoglycan complex
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6521426B1 (en) 1998-04-08 2003-02-18 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Preparation of recombinant adenovirus carrying a rep gene of adeno-associated virus
FR2778413B1 (en) 1998-05-07 2000-08-04 Immunotech Sa NOVEL REAGENTS AND METHOD FOR LYSIS OF ERYTHROCYTES
EP1078096A1 (en) 1998-05-11 2001-02-28 Ariad Gene Therapeutics, Inc. Multiviral compositions and uses thereof
US6436392B1 (en) 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
EP1849872A1 (en) 1998-05-20 2007-10-31 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
EP1621625B1 (en) 1998-05-27 2009-05-13 Genzyme Corporation AAV vectors for the manufacture of medicaments for convection enhanced delivery
EP1082445A2 (en) 1998-05-27 2001-03-14 Cell Genesys, Inc. Adeno-associated viral vector-mediated expression of factor viii activity
CA2329259C (en) * 1998-05-27 2003-08-05 Avigen, Inc. Convection-enhanced delivery of aav vectors
EP1080218A1 (en) 1998-05-27 2001-03-07 University of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient
WO1999061601A2 (en) 1998-05-28 1999-12-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aav5 vector and uses thereof
US6984517B1 (en) 1998-05-28 2006-01-10 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector and uses thereof
GB2338236B (en) 1998-06-13 2003-04-09 Aea Technology Plc Microbiological cell processing
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US6416992B1 (en) 1998-10-13 2002-07-09 Avigen, Inc. Compositions and methods for producing recombinant adeno-associated virus
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
JP2002528087A (en) 1998-10-27 2002-09-03 クルセル ホランド ベー ヴェー Improved AAV vector production
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
US6225113B1 (en) 1998-12-04 2001-05-01 Genvec, Inc. Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
US6387368B1 (en) 1999-02-08 2002-05-14 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
DE19905501B4 (en) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie A method of producing a recombinant adeno-associated virus, suitable compositions therefor, and use for the manufacture of a medicament
US6509150B1 (en) 1999-03-05 2003-01-21 Universite De Nantes Compositions and methods for recombinant Adeno-Associated Virus production
JP4693244B2 (en) 1999-03-18 2011-06-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Compositions and methods for helperless production of recombinant adeno-associated virus
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
AU4807400A (en) 1999-04-30 2000-11-17 University Of Florida Adeno-associated virus-delivered ribozyme compositions and methods of use
EP1183380A1 (en) 1999-06-02 2002-03-06 The Trustees Of The University Of Pennsylvania Compositions and methods useful for production of recombinant viruses which require helper viruses
JP2003507063A (en) 1999-08-20 2003-02-25 ジョンズ ホプキンス ユニバーシティ スクール オブ メディシン Methods and compositions for constructing and using fusion libraries
AU1071701A (en) 1999-09-29 2001-04-30 Trustees Of The University Of Pennsylvania, The Methods for rapid peg-modification of viral vectors, compositions for enhanced gene transduction, compositions with enhanced physical stability, and uses therefor
US6365394B1 (en) 1999-09-29 2002-04-02 The Trustees Of The University Of Pennsylvania Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
CA2386546A1 (en) 1999-10-07 2001-04-12 University Of Iowa Research Foundation Adeno-associated viruses and uses thereof
US7241447B1 (en) 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
AU1436401A (en) 1999-10-21 2001-05-14 Board Of Trustees Of The University Of Arkansas, The RepO-associated virus AAV REP78 major regulatory protein, mutants thereof and uses thereof
WO2001036623A2 (en) 1999-11-05 2001-05-25 Avigen, Inc. Ecdysone-inducible adeno-associated virus expression vectors
WO2001036603A2 (en) 1999-11-17 2001-05-25 Avigen, Inc. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
WO2001042444A2 (en) 1999-12-10 2001-06-14 Ariad Gene Therapeutics, Inc. Methods for expression of genes in primates
US7638120B2 (en) 2000-03-14 2009-12-29 Thomas Jefferson University High transgene expression of a pseudotyped adeno-associated virus type
CA2373110A1 (en) 2000-03-14 2001-09-20 Neurologix, Inc. Production of chimeric capsid vectors
US6855314B1 (en) 2000-03-22 2005-02-15 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector for transducing brain cells and lung cells
US6468524B1 (en) 2000-03-22 2002-10-22 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services AAV4 vector and uses thereof
US7048920B2 (en) 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
GB0009887D0 (en) 2000-04-20 2000-06-07 Btg Int Ltd Cytotoxic agents
US20030013189A1 (en) 2000-04-28 2003-01-16 Wilson James M. Compositions and methods useful for non-invasive delivery of therapeutic molecules to the bloodstream
AU5557501A (en) 2000-04-28 2001-11-12 Univ Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
AU2001257611A1 (en) 2000-04-28 2001-11-12 Avigen, Inc. Polynucleotides for use in recombinant adeno-associated virus virion production
US6780409B2 (en) 2000-05-23 2004-08-24 Thomas Jefferson University Glutamic acid decarboxylase (GAD) based delivery system
US20020106381A1 (en) 2000-06-13 2002-08-08 High Katherine A. Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
DE60128916T2 (en) 2000-07-18 2007-09-20 Takeda Pharmaceutical Co. Ltd. NEW, PHYSIOLOGICALLY ACTIVE PEPTIDE AND ITS USE
US6329181B1 (en) 2000-08-07 2001-12-11 Neurologix, Inc. Helper functions for recombinant vector production
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
EP1311699B1 (en) 2000-08-17 2007-07-04 Keiya Ozawa Adeno-associated virus-mediated delivery of angiogenic factors
DE10044384A1 (en) 2000-09-08 2002-04-18 Medigene Ag Host cells for packaging recombinant adeno-associated virus (rAAV), process for their preparation and their use
FR2813891B1 (en) 2000-09-14 2005-01-14 Immunotech Sa MULTIFUNCTIONAL REAGENT FOR ERYTHROCYTES INVOLVING CARBAMATES AND APPLICATIONS
GB0024550D0 (en) * 2000-10-06 2000-11-22 Oxford Biomedica Ltd
JP2002153278A (en) 2000-11-22 2002-05-28 Hisamitsu Pharmaceut Co Inc Cell for producing virus vector, method for producing the virus vector and method for producing virus vector using the cell
WO2002070719A2 (en) 2001-01-19 2002-09-12 Trustees Of The University Of Pennsylvania Regulatable gene expression system
US20030147853A1 (en) 2001-03-14 2003-08-07 Mcclelland Alan Recombinant adeno-associated virus-mediated gene transfer via retroductal infusion of virions
US7588757B2 (en) 2001-03-14 2009-09-15 Genzyme Corporation Methods of treating Parkinson's disease using recombinant adeno-associated virus virions
US6841357B1 (en) 2001-03-30 2005-01-11 Stratagene California Method and kits for titering adeno-associated virus vectors
US7182944B2 (en) 2001-04-25 2007-02-27 The United States Of America As Represented By The Department Of Health And Human Services Methods of increasing distribution of nucleic acids
US20030096264A1 (en) * 2001-06-18 2003-05-22 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (MPHTS)
AU2002322285A1 (en) 2001-06-22 2003-01-08 The Trustees Of The University Of Pennsylvania Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
US20040136963A1 (en) 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
US8241622B2 (en) 2001-07-13 2012-08-14 University Of Iowa Research Foundation Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
EP1279740A1 (en) 2001-07-26 2003-01-29 Vrije Universiteit Brussel Recombinant vector derived from adeno-associated virus for gene therapy
AU2002349877B2 (en) 2001-08-08 2007-10-11 The Trustees Of The University Of Pennsylvania Method for purification of viral vectors having proteins which bind sialic acid
US20030092161A1 (en) 2001-09-19 2003-05-15 The Trustees Of The University Of Pennsylvania Compositions and methods for production of recombinant viruses, and uses therefor
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
AU2002360355B2 (en) 2001-11-09 2005-07-07 Government Of The United States Of America, Department Of Health And Human Services Production of adeno-associated virus in insect cells
CN103555678B (en) 2001-11-13 2018-02-09 宾夕法尼亚大学托管会 The method for the novel sequences that detection and/or identification adeno-associated virus (AAV) sequence and separation are identified
HU230488B1 (en) 2001-11-21 2016-08-29 The Trustees Of The University Of Pennsylvania Simian adeniovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
EP1944043A1 (en) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
JP2005517394A (en) 2001-12-12 2005-06-16 エフ エイチ フォールディング アンド カンパニー リミテッド Composition for virus preservation
EP1463805B1 (en) 2001-12-17 2014-10-22 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
ES2717377T3 (en) 2001-12-17 2019-06-20 Univ Pennsylvania Sequences of serotype 8 of adeno-associated virus (AAV), vectors containing them and uses thereof
CA2469658A1 (en) 2001-12-19 2003-07-03 Lijun Wang Adeno-associated virus-mediated delivery of gdnf to skeletal muscles
EP1468116A2 (en) 2002-01-16 2004-10-20 Dynal Biotech ASA Method for isolating nucleic acids and protein from a single sample
PT1504108E (en) 2002-02-01 2013-06-12 Oxford Biomedica Ltd Lentiviral vector
GB0208390D0 (en) 2002-04-11 2002-05-22 Univ London Adeno-associated virus producer system
US20030198620A1 (en) 2002-04-16 2003-10-23 Keiya Ozawa Method of treating amino acid metabolic disorders using recombinant adeno-associated virus virions
JP3943048B2 (en) 2002-04-29 2007-07-11 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Method for direct rescue and amplification of integrated virus from cellular DNA of tissue
MXPA04010603A (en) 2002-04-30 2004-12-13 Oncolytics Biotech Inc Improved viral purification methods.
AU2003295312B2 (en) 2002-05-01 2008-08-14 University Of Florida Research Foundation, Inc. Improved rAAV expression systems for genetic modification of specific capsid proteins
PT1506287E (en) 2002-05-14 2007-07-17 Merck & Co Inc Methods of adenovirus purification
US7419817B2 (en) 2002-05-17 2008-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
US20070015238A1 (en) 2002-06-05 2007-01-18 Snyder Richard O Production of pseudotyped recombinant AAV virions
EP1572943B1 (en) 2002-08-29 2015-04-22 The Board of Trustees of The Leland S. Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US7169612B2 (en) 2002-11-11 2007-01-30 Sanofi-Aventis Deutschland Gmbh Use of EDG2 receptor in an animal model of heart failure
EP1418185A1 (en) 2002-11-11 2004-05-12 Aventis Pharma Deutschland GmbH Use of EDG2 receptor in an animal model of heart failure
US7510872B2 (en) 2003-02-26 2009-03-31 Nationwide Children's Hospital Recombinant adeno-associated virus production
US20070172460A1 (en) 2003-03-19 2007-07-26 Jurgen Kleinschmidt Random peptide library displayed on aav vectors
WO2004108922A2 (en) 2003-04-25 2004-12-16 The Trustees Of The University Of Pennsylvania Use of aav comprising a capsid protein from aav7 or aav8 for the delivery of genes encoding apoprotein a or e genes to the liver
US8927269B2 (en) 2003-05-19 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Avian adenoassociated virus and uses thereof
EP2281877A3 (en) 2003-05-21 2011-06-01 Genzyme Corporation Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
JP4888876B2 (en) 2003-06-13 2012-02-29 田平 武 Recombinant adeno-associated virus vector for the treatment of Alzheimer's disease
EP2657247B1 (en) * 2003-06-19 2017-03-22 Genzyme Corporation AAV virions with decreased immunoreactivity and uses therefor
ES2478625T3 (en) 2003-06-20 2014-07-22 The Trustees Of The University Of Pennsylvania Method of generating chimeric adenoviruses and uses of such chimeric adenoviruses
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
EP1649028B1 (en) 2003-07-25 2012-08-22 Genvec, Inc. Adenoviral vector-based vaccines
CA2533701A1 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US20070073264A1 (en) 2003-09-26 2007-03-29 The Trustees Of The University Of Pennsylvania Methods, compositions and apparatus for delivering heterologous molecules to cells
ES2616016T3 (en) 2003-09-30 2017-06-09 The Trustees Of The University Of Pennsylvania Adeno-associated virus clades (AAV), sequences, vectors that contain them and uses thereof
CN1897977A (en) * 2003-10-20 2007-01-17 Ns基因公司 In vivo gene therapy of parkinson's disease
ES2361000T3 (en) 2004-04-28 2011-06-13 The Trustees Of The University Of Pennsylvania SEQUENTIAL SUPPLY OF IMMUNOGENIC MOLECULES THROUGH ADMINISTRATIONS OF AN ADENOVIRUS AND AN ADENO-ASSOCIATED VIRUS.
WO2005116224A2 (en) * 2004-05-18 2005-12-08 Children's Memorial Hospital Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
ES2647477T3 (en) 2004-06-01 2017-12-21 Genzyme Corporation Compositions and methods to prevent aggregation of the AAV vector
DK1807009T3 (en) 2004-10-05 2015-03-02 Genzyme Corp Stair shaped needle
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
CN1286981C (en) 2004-11-30 2006-11-29 华中科技大学同济医学院附属同济医院 Recombinant adeno-associated virus expressing human CYP2J2 antisense gene and preparation method thereof
JP2008523093A (en) 2004-12-09 2008-07-03 ジェンザイム・コーポレイション Regulated expression of transgenes in the mammalian central nervous system
US8614101B2 (en) 2008-05-20 2013-12-24 Rapid Pathogen Screening, Inc. In situ lysis of cells in lateral flow immunoassays
US7625570B1 (en) 2005-03-10 2009-12-01 The Regents Of The University Of California Methods for purifying adeno-associated virus
WO2006102072A2 (en) 2005-03-23 2006-09-28 The Trustees Of The University Of Pennsylvania Use of a pa131 polypeptide in treatment of atherosclerosis
WO2006110689A2 (en) 2005-04-07 2006-10-19 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
EP3058959B1 (en) 2005-05-02 2019-01-30 Genzyme Corporation Gene therapy for neurometabolic disorders
AU2006283189B2 (en) 2005-08-23 2013-01-31 The Regents Of The University Of California Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery
TR201909609T4 (en) 2005-08-23 2019-07-22 Univ Pennsylvania DNA containing modified nucleosides and methods of use.
EP1857552A1 (en) 2006-05-20 2007-11-21 Cargill Incorporated Thermostable xylose isomerase enzyme
EP1945779B1 (en) 2005-10-20 2013-03-06 UniQure IP B.V. Improved aav vectors produced in insect cells
US9150882B2 (en) 2006-01-31 2015-10-06 The Board Of Trustees Of The Leland Stanford Junior University Self-complementary parvoviral vectors, and methods for making and using the same
US7588772B2 (en) * 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
WO2007127803A2 (en) 2006-04-25 2007-11-08 The Regents Of The University Of California Administration of growth factors for the treatment of cns disorders
DE602007004470D1 (en) 2006-04-28 2010-03-11 Univ Pennsylvania MODIFIED ADENOVIRUS HEXON PROTEIN AND APPLICATIONS THEREOF
CN101495624A (en) 2006-04-28 2009-07-29 宾夕法尼亚州立大学托管会 Modified AAV vectors having reduced capsid immunogenicity and use thereof
JP5268890B2 (en) 2006-04-28 2013-08-21 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア AAV scale adaptability manufacturing method
US20080003565A1 (en) 2006-05-02 2008-01-03 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Viral nucleic acid microarray and method of use
JP5551432B2 (en) 2006-05-25 2014-07-16 サンガモ バイオサイエンシーズ， インコーポレイテッド Methods and compositions for gene inactivation
EP2037948B1 (en) 2006-05-30 2016-04-13 Mayo Foundation For Medical Education And Research Detecting and treating dementia
ES2596885T3 (en) 2006-06-07 2017-01-12 Genzyme Corporation Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
CN104087591A (en) 2006-06-19 2014-10-08 阿斯克肋匹奥生物制药公司 Modified factor viii and factor ix genes and vectors for gene therapy
CN101506369B (en) 2006-06-21 2014-02-12 尤尼克尔生物制药股份有限公司 Vectors with modified initiation codon for translation of AAV-REP78 useful for production of AAV in insect cells
AU2007275010B2 (en) 2006-07-21 2013-06-20 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
WO2008024998A2 (en) 2006-08-24 2008-02-28 Virovek, Inc. Expression in insect cells of genes with overlapping open reading frames, methods and compositions therefor
ES2569365T3 (en) 2006-11-29 2016-05-10 Nationwide Children's Hospital Inhibition of myostatin for muscle enhancement and / or improvement of muscle function
KR20090123873A (en) 2007-02-02 2009-12-02 바이오겐 아이덱 엠에이 인코포레이티드 Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
US20120322861A1 (en) 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
US9611302B2 (en) 2007-04-09 2017-04-04 University Of Florida Research Foundation, Inc. High-transduction-efficiency RAAV vectors, compositions, and methods of use
CA2720097C (en) 2007-04-09 2016-07-19 University Of Florida Research Foundation, Inc. Raav vector compositions having tyrosine-modified capsid proteins and methods for use
US9725485B2 (en) 2012-05-15 2017-08-08 University Of Florida Research Foundation, Inc. AAV vectors with high transduction efficiency and uses thereof for gene therapy
WO2008128251A1 (en) 2007-04-17 2008-10-23 The Children's Hospital Of Philadelphia Humanized viral vectors and methods of use thereof
EP2012122A1 (en) 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
US20100203083A1 (en) 2007-05-31 2010-08-12 Medigene Ag Mutated structural protein of a parvovirus
PL3252161T3 (en) 2007-06-06 2022-03-07 Genzyme Corporation Gene therapy for lysosomal storage diseases
ES2377765T3 (en) 2007-06-29 2012-03-30 F. Hoffmann-La Roche Ag Promoter
ES2615180T3 (en) 2007-07-14 2017-06-05 University Of Iowa Research Foundation Methods and compositions for the treatment of brain diseases
EP3093345B8 (en) 2007-07-26 2019-07-24 UniQure IP B.V. Baculoviral vectors comprising repeated coding sequences with differential codon biases
US8420372B2 (en) 2007-09-04 2013-04-16 Alexander Bello Porcine adeno-associated viruses
JP2010538675A (en) 2007-09-19 2010-12-16 アムステルダム モレキュラー セラピューティクス ビー．ブイ． Use of the AAV replication mechanism to improve protein production
WO2009051421A2 (en) 2007-10-18 2009-04-23 Lg Electronics Inc. Method and system for transmitting and receiving signals
US8642341B2 (en) 2007-11-02 2014-02-04 Cornell University Materials and methods for gene mediated therapy of psychiatric disorders
PL2220241T3 (en) 2007-11-28 2017-06-30 The Trustees Of The University Of Pennsylvania Adenovirus comprising a Simian E Adenovirus SAdV-39 capsid hexon protein and uses thereof
AU2008350937B2 (en) 2007-11-28 2014-10-09 The Trustees Of The University Of Pennsylvania Simian subfamily C adenovirus SAdV-31 and uses thereof
WO2009073103A2 (en) 2007-11-28 2009-06-11 The Trustees Of The University Of Pennsylvania Simian subfamily b adenoviruses sadv-28,27,-29,-32,-33, and -35 and uses thereof
CN101977934B (en) 2008-01-18 2014-09-17 健泰科生物技术公司 Methods and compositions for targeting polyubiquitin
CA2713338C (en) 2008-01-29 2021-10-26 Applied Genetic Technologies Corporation Recombinant virus production using mammalian cells in suspension
CA2715924C (en) 2008-02-19 2021-01-12 Andrew Christian BAKKER Optimisation of expression of parvoviral rep and cap proteins in insect cells
EP2250255A2 (en) 2008-03-04 2010-11-17 The Trustees of the University of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
WO2009120978A2 (en) 2008-03-27 2009-10-01 The Ohio State University Treatment of metabolic-related disorders using hypothalamic gene transfer of bdnf and compositions therfor
WO2009134681A2 (en) 2008-04-30 2009-11-05 The Trustees Of The University Of Pennsylvania Aav7 viral vectors for targeted delivery of rpe cells
WO2009137006A2 (en) 2008-04-30 2009-11-12 The University Of North Carolina At Chapel Hill Directed evolution and in vivo panning of virus vectors
GB2472964B (en) 2008-05-20 2013-04-24 Eos Neuroscience Inc Vectors for delivery of light-sensitive proteins and methods of use
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
US20110171262A1 (en) 2008-06-17 2011-07-14 Andrew Christian Bakker Parvoviral capsid with incorporated gly-ala repeat region
US8945885B2 (en) 2008-07-03 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Minicircle DNA vector preparations and methods of making and using the same
JP2012503980A (en) 2008-09-29 2012-02-16 アムステルダム モレキュラー セラピューティクス （エーエムティー） ビー．ブイ． Porphobilinogen deaminase gene therapy
DK2350269T3 (en) 2008-10-31 2015-12-07 Univ Pennsylvania ABE ADENOVIRUS WITH SADV-46 HEXONCAPSIDE PROTEINS AND APPLICATIONS THEREOF
EP2362912A1 (en) 2008-11-14 2011-09-07 Life Technologies Corporation Compositions and methods for engineering cells
US9415121B2 (en) 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
ES2634118T3 (en) 2009-02-11 2017-09-26 The University Of North Carolina At Chapel Hill Modified virus vectors and methods to manufacture and use them
US9464119B2 (en) 2009-03-04 2016-10-11 Deutsches Krebsforschungszentrum Assembly activating protein (AAP) and its use for the manufacture of parvovirus particles essentially consisting of VP3
JP2012521750A (en) 2009-03-27 2012-09-20 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ Methods and compositions for the treatment of cirrhosis and liver fibrosis
ES2724122T3 (en) 2009-04-30 2019-09-06 Univ Pennsylvania Compositions for directing conductive airway cells comprising adeno-associated virus constructs
CN102414313B (en) 2009-05-01 2014-04-02 雷德生物科技股份公司 Recombinant virus-like particles encoded by multi-gene vector
SG175409A1 (en) 2009-05-02 2011-12-29 Genzyme Corp Gene therapy for neurodegenerative disorders
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
EP2772542B1 (en) 2009-05-28 2016-12-28 Deutsches Krebsforschungszentrum Modified AAV capsid polypeptides
CA2762203A1 (en) 2009-05-29 2010-12-02 Soumitra Roy Simian adenovirus 41 and uses thereof
SG176283A1 (en) 2009-06-16 2012-01-30 Genzyme Corp Improved methods for purification of recombinant aav vectors
BR112012000421A2 (en) 2009-07-06 2019-09-24 Alnylam Pharmaceuticals Inc compositions and methods for enhancing the production of a biological product.
EP2292781A1 (en) 2009-08-17 2011-03-09 Genethon Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions
WO2011038187A1 (en) 2009-09-25 2011-03-31 The Trustees Of The University Of Pennsylvania Controlled adeno-associated virus (aav) diversification and libraries prepared therefrom
EP2498825B1 (en) 2009-11-09 2017-03-29 Genepod Therapeutics Ab Novel viral vector construct for neuron specific continuous dopa synthesis in vivo
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
EP2524037B1 (en) 2010-01-12 2018-05-16 The University Of North Carolina At Chapel Hill Restrictive inverted terminal repeats for viral vectors
WO2011091419A2 (en) 2010-01-25 2011-07-28 New York Universiy Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery
US9169492B2 (en) 2010-02-05 2015-10-27 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
EP2545165B1 (en) 2010-03-11 2020-07-29 uniQure IP B.V. Mutated rep encoding sequences for use in aav production
US9546112B2 (en) 2010-03-22 2017-01-17 Association Institut De Myologie Methods of increasing efficiency of vector penetration of target tissue
KR20130040844A (en) 2010-03-29 2013-04-24 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Pharmacologically induced transgene ablation system
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
WO2011122950A1 (en) 2010-04-01 2011-10-06 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Monomeric duplex aav vectors
EP3514232A1 (en) * 2010-04-23 2019-07-24 University of Massachusetts Cns targeting aav vectors and methods of use thereof
CA2833912C (en) 2010-04-23 2021-09-21 University Of Massachusetts Aav-based treatment of cholesterol-related disorders
WO2011133874A1 (en) 2010-04-23 2011-10-27 University Of Massachusetts Multicistronic expression constructs
US9839696B2 (en) 2010-04-30 2017-12-12 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
EP2605798A1 (en) * 2010-07-12 2013-06-26 Universidad Autònoma de Barcelona Gene therapy composition for use in diabetes treatment
US8808684B2 (en) 2010-09-10 2014-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epidermal growth factor receptor (EGFR) and methods of use in adenoviral-associated virus type 6 (AAV6) transduction
US9102943B2 (en) 2010-10-05 2015-08-11 Takara Bio Inc. Method for producing virus vector
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
WO2012051343A1 (en) 2010-10-12 2012-04-19 The Children's Hospital Of Philadelphia Methods and compositions for treating hemophilia b
EP2634253B1 (en) * 2010-10-27 2016-05-11 Jichi Medical University Adeno-associated virus virions for transferring genes into neural cells
WO2012061786A1 (en) 2010-11-05 2012-05-10 Brandeis University Ice cleaved alpha-synuclein a biomarker
EP2637702A4 (en) 2010-11-11 2014-11-26 Univ Miami Methods, compositions, cells, and kits for treating ischemic injury
WO2012071318A2 (en) 2010-11-23 2012-05-31 The Trustees Of The University Of Pennsylvania Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof
WO2012109570A1 (en) * 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
JP6224459B2 (en) 2011-02-17 2017-11-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Compositions and methods for altering tissue specificity and improving AAV9-mediated gene transfer
GB201103062D0 (en) 2011-02-22 2011-04-06 Isis Innovation Method
WO2012115980A1 (en) * 2011-02-22 2012-08-30 California Institute Of Technology Delivery of proteins using adeno-associated virus (aav) vectors
US20120220648A1 (en) * 2011-02-24 2012-08-30 National Taiwan University Hospital Method of Treating Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency Using Adeno-Associated Virus (AAV)-AADC Vector
EP2500434A1 (en) 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
CN103476399A (en) 2011-04-18 2013-12-25 独立行政法人国立精神·神经医疗研究中心 Drug delivery particles and method for producing same
EP3699286A1 (en) 2011-04-20 2020-08-26 The Trustees of the University of Pennsylvania Regimens and compositions for aav-mediated passive immunization of airborne pathogens
CA2870511C (en) 2011-04-21 2023-08-08 University Of Massachusetts Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
KR102121355B1 (en) 2011-04-22 2020-06-11 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Adeno-associated virus virions with variant capsid and methods of use thereof
WO2012158757A1 (en) 2011-05-16 2012-11-22 The Trustees Of The University Of Pennsylvania Proviral plasmids for production of recombinant adeno-associated virus
WO2012159006A2 (en) 2011-05-18 2012-11-22 University Of Florida Research Foundation, Inc. Polypeptides and vectors for targeting her2/neu expressing cells and uses thereof
US20120295960A1 (en) * 2011-05-20 2012-11-22 Oxford Biomedica (Uk) Ltd. Treatment regimen for parkinson's disease
JP6153516B2 (en) 2011-06-06 2017-06-28 バイオカーティス エヌベー Selective lysis of cells by ionic surfactants.
US10480010B2 (en) 2011-07-27 2019-11-19 Genethon Baculovirus expression systems
EP2744895B1 (en) 2011-09-08 2015-10-14 UniQure IP B.V. Removal of contaminating viruses from aav preparations
WO2013036889A1 (en) 2011-09-09 2013-03-14 University Of Washington Retrograde transport peptide and use of same for delivery to central nervous system
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
US9441206B2 (en) 2011-10-28 2016-09-13 The University Of North Carolina At Chapel Hill Cell line for production of adeno-associated virus
CA2856137A1 (en) 2011-11-22 2013-05-30 The Children's Hospital Of Philadelphia Virus vectors for highly efficient transgene delivery
WO2013078316A1 (en) 2011-11-23 2013-05-30 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
WO2013078199A2 (en) 2011-11-23 2013-05-30 Children's Medical Center Corporation Methods for enhanced in vivo delivery of synthetic, modified rnas
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
PL2814513T3 (en) 2012-02-14 2018-06-29 The Regents Of The University Of California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
AU2013221212B2 (en) 2012-02-17 2018-08-09 The Children's Hospital Of Philadelphia AAV vector compositions and methods for gene transfer to cells, organs and tissues
CA2870736C (en) 2012-04-18 2021-11-02 The Children's Hospital Of Philadelphia Composition and methods for highly efficient gene transfer using aav capsid variants
US20140162319A2 (en) 2012-05-02 2014-06-12 Sangeetha Hareendran Nucleotide sequences, methods, kit and a recombinant cell thereof
US9163259B2 (en) 2012-05-04 2015-10-20 Novartis Ag Viral vectors for the treatment of retinal dystrophy
KR102108586B1 (en) 2012-05-08 2020-05-07 머크 샤프 앤드 돔 코포레이션 Permeable glycosidase inhibitors and uses thereof
EP3470523A1 (en) 2012-05-09 2019-04-17 Oregon Health & Science University Adeno associated virus plasmids and vectors
TWI698240B (en) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 Treatment of amd using aav sflt-1
US10294281B2 (en) 2012-05-15 2019-05-21 University Of Florida Research Foundation, Incorporated High-transduction-efficiency rAAV vectors, compositions, and methods of use
MX358019B (en) 2012-05-18 2018-08-02 Univ Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof.
JP6366581B2 (en) 2012-07-06 2018-08-08 ユニバーシティー オブ アイオワ リサーチ ファウンデーション Modified adeno-associated virus vector composition
CN104603272B (en) 2012-07-06 2017-11-07 宝生物工程株式会社 The cell of adeno-associated virus vector can be produced
EP3769789A1 (en) 2012-08-01 2021-01-27 Nationwide Children's Hospital Intrathecal delivery of recombinant adeno-associated virus 9
EP2890791B1 (en) 2012-08-31 2019-03-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Aav mediated aquaporin gene transer to treat sjogren's syndrome
EP3738974A1 (en) 2012-09-28 2020-11-18 The University of North Carolina at Chapel Hill Aav vectors targeted to oligodendrocytes
US9733237B2 (en) 2012-10-31 2017-08-15 The Trustees Of Columbia University In The City Of New York Methods for identifying candidates for the treatment of neurodegenerative diseases
DK3327127T3 (en) 2012-12-12 2021-06-28 Broad Inst Inc PERFORMANCE, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTIC APPLICATIONS
EP2940131B1 (en) 2012-12-25 2019-02-20 Takara Bio Inc. Aav variant
RU2676733C2 (en) 2013-01-08 2019-01-10 Джензим Корпорейшн Use of inos inhibitors to increase viral yield in culture
US9066966B2 (en) 2013-02-01 2015-06-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia
ES2741502T3 (en) 2013-02-08 2020-02-11 Univ Pennsylvania AAV8 capsid modified for gene transfer for retinal therapies
JP2016514152A (en) 2013-03-13 2016-05-19 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア Adeno-associated virus vector and method of use thereof
EP3517612A1 (en) 2013-03-15 2019-07-31 The University of North Carolina At Chapel Hill Synthetic adeno-associated virus inverted terminal repeats
JP2016517278A (en) 2013-03-15 2016-06-16 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ Vectors comprising stuffer / filler polynucleotide sequences and methods of use thereof
JP6516725B2 (en) 2013-04-08 2019-05-22 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン Chimeric Adeno-Associated Virus / Bocavirus Parvovirus Vector
EP2792742A1 (en) 2013-04-17 2014-10-22 Universitätsklinikum Hamburg-Eppendorf (UKE) Gene-therapy vectors for treating cardiomyopathy
DK2986635T3 (en) 2013-04-18 2019-01-28 Fond Telethon EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS
US9862945B2 (en) 2013-04-20 2018-01-09 Research Institute At Nationwide Children's Hospital Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs
WO2015012924A2 (en) 2013-04-29 2015-01-29 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
CN115120745A (en) 2013-05-15 2022-09-30 明尼苏达大学董事会 Adeno-associated virus-mediated gene transfer to the central nervous system
US10006049B2 (en) 2013-05-16 2018-06-26 University Of Florida Research Foundation, Incorporated Hairpin mRNA elements and methods for the regulation of protein translation
CA2907799A1 (en) 2013-05-31 2014-12-04 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
WO2014201308A1 (en) 2013-06-12 2014-12-18 Washington University Endothelial-targeted adenoviral vectors, methods and uses therefor
WO2014201252A2 (en) 2013-06-13 2014-12-18 Shire Human Genetic Therapies, Inc. Messenger rna based viral production
PL3024498T3 (en) 2013-07-22 2020-05-18 The Children's Hospital Of Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
PT3024497T (en) 2013-07-26 2021-08-23 Univ Iowa Res Found Methods and compositions for treating brain diseases
ITTO20130669A1 (en) 2013-08-05 2015-02-06 Consiglio Nazionale Ricerche ADENO-ASSOCIATED MOMCULAR-SPECIFIC VECTOR AND ITS EMPLOYMENT IN THE TREATMENT OF MUSCLE PATHOLOGIES
WO2015031686A1 (en) 2013-08-30 2015-03-05 Amgen Inc. High titer recombinant aav vector production in adherent and suspension cells
CA3178384A1 (en) 2013-09-12 2015-03-19 Biomarin Pharmaceutical Inc. Adeno-associated virus factor viii vectors
EP3044318B1 (en) 2013-09-13 2019-05-01 California Institute of Technology Selective recovery
CA2930549A1 (en) 2013-09-26 2015-04-02 University Of Florida Research Foundation, Inc. Synthetic combinatorial aav capsid library for targeted gene therapy
WO2015044292A1 (en) 2013-09-26 2015-04-02 Universitat Autonoma De Barcelona Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease
EP3744730A1 (en) 2013-10-11 2020-12-02 Massachusetts Eye & Ear Infirmary Methods of predicting ancestral virus sequences and uses thereof
JP6873699B2 (en) 2013-10-24 2021-05-19 ユニキュアー アイピー ビー．ブイ． Treatment of neurological disorders with adeno-associated virus (AAV) containing the AAV5 capsid protein
US20160272687A1 (en) 2013-11-08 2016-09-22 The Board Of Trustees Of The University Of Arkansas Adeno-associated virus "x" oncogene
CN105934515B (en) 2013-11-26 2020-08-04 美国政府(由卫生和人类服务部的部长所代表) Adeno-associated virus vectors for treatment of glycogen storage disease
JP6567974B2 (en) 2013-11-29 2019-08-28 タカラバイオ株式会社 Method for quantifying adeno-associated virus
CA2932624C (en) 2013-12-09 2023-03-28 Texas Heart Institute Treating cardiac conditions using shrna or sirna targeting salvador (sav1)
CN106103705A (en) 2013-12-12 2016-11-09 布罗德研究所有限公司 Nucleotide repeats compositions and the using method of CRISPR cas system in obstacle
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
WO2015104403A1 (en) 2014-01-09 2015-07-16 Genethon Methods for diagnosing or monitoring muscular dystrophies
WO2015106273A2 (en) 2014-01-13 2015-07-16 Trustees Of Boston University Methods and assays relating to huntingtons disease and parkinson's disease
GB201401707D0 (en) 2014-01-31 2014-03-19 Sec Dep For Health The Adeno-associated viral vectors
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
WO2015124546A1 (en) 2014-02-19 2015-08-27 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii- Cnic Aav vectors for the treatment of ischemic and non-ischemic heart disease
WO2015127128A2 (en) 2014-02-19 2015-08-27 University Of Massachusetts Recombinant aavs having useful transcytosis properties
WO2015124540A1 (en) 2014-02-19 2015-08-27 F. Hoffmann-La Roche Ag Blood brain barrier shuttle
US20170007720A1 (en) 2014-02-21 2017-01-12 University Of Florida Research Foundation, Inc. Methods and compositions for gene delivery to on bipolar cells
WO2015127351A1 (en) 2014-02-24 2015-08-27 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
WO2015131076A1 (en) 2014-02-27 2015-09-03 Yale University Nlrp6 inflammasome intestinal epithelium mucus secretion
EP3113787B1 (en) 2014-03-04 2019-12-04 University of Florida Research Foundation, Inc. Improved raav vectors and methods for transduction of photoreceptors and rpe cells
EP3119415A4 (en) 2014-03-07 2017-11-29 The Arizona Board of Regents on behalf of the University of Arizona Non-narcotic crmp2 peptides targeting sodium channels for chronic pain
HUE051311T2 (en) 2014-03-09 2021-03-01 Univ Pennsylvania Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency
PT3117005T (en) 2014-03-10 2024-07-30 Uniqure Ip Bv Further improved aav vectors produced in insect cells
EP3126506A4 (en) 2014-04-03 2017-11-22 Braingene AB Gene expression system and regulation thereof
WO2015157070A2 (en) 2014-04-09 2015-10-15 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating cystic fibrosis
EP2933335A1 (en) 2014-04-18 2015-10-21 Genethon A method of treating peripheral neuropathies and motor neuron diseases
ES2876409T3 (en) 2014-04-25 2021-11-12 Univ Pennsylvania Variants of RLBD and their use in compositions to reduce cholesterol levels
WO2015164786A1 (en) 2014-04-25 2015-10-29 University Of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
WO2015173436A1 (en) 2014-05-16 2015-11-19 Vrije Universiteit Brussel Genetic correction of myotonic dystrophy type 1
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
EP3154560B1 (en) 2014-06-13 2019-03-13 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods and materials for increasing viral vector infectivity
US10781459B2 (en) 2014-06-20 2020-09-22 University Of Florida Research Foundation, Incorporated Methods of packaging multiple adeno-associated virus vectors
EP2960336A1 (en) 2014-06-27 2015-12-30 Genethon Efficient systemic treatment of dystrophic muscle pathologies
US10526583B2 (en) 2014-07-02 2020-01-07 University Of Florida Research Foundation, Incorporated Compositions and methods for purifying recombinant adeno-associated virus
US10023846B2 (en) 2014-07-10 2018-07-17 Takara Bio Inc. Production method for non-enveloped virus particles
WO2016019144A2 (en) 2014-07-30 2016-02-04 Sangamo Biosciences, Inc. Gene correction of scid-related genes in hematopoietic stem and progenitor cells
US10392622B2 (en) 2014-08-01 2019-08-27 The Trustees Of The University Of Pennsylvania Compositions and methods for self-regulated inducible gene expression
US10370432B2 (en) 2014-10-03 2019-08-06 University Of Massachusetts Heterologous targeting peptide grafted AAVS
EP3795580A1 (en) 2014-10-03 2021-03-24 University of Massachusetts High efficiency library-identified aav vectors
US10842886B2 (en) 2014-10-10 2020-11-24 Research Institute At Nationwide Children's Hospital Guided injections for AAV gene transfer to muscle
RU2020140209A (en) 2014-10-21 2021-01-25 Юниверсити Оф Массачусетс RECOMBINANT AAV OPTIONS AND THEIR APPLICATIONS
AU2015342997B2 (en) 2014-11-05 2021-11-18 Research Institute At Nationwide Children's Hospital Methods and materials for producing recombinant viruses in eukaryotic microalgae
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
CA2966964A1 (en) 2014-11-19 2016-05-26 Michal Novak Humanized tau antibodies in alzheimer's disease
WO2016081927A2 (en) 2014-11-21 2016-05-26 University Of Florida Research Foundation, Inc. Genome-modified recombinant adeno-associated virus vectors
WO2016081811A1 (en) 2014-11-21 2016-05-26 The University Of North Carolina At Chapel Hill Aav vectors targeted to the central nervous system
EA035747B1 (en) 2014-11-28 2020-08-05 ЮНИКЬЮРЕ АйПи Б.В. Dna impurities in a composition comprising a parvoviral virion
EP3230441A4 (en) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
US10907176B2 (en) 2015-01-14 2021-02-02 The University Of North Carolina At Chapel Hill Methods and compositions for targeted gene transfer
US20180008727A1 (en) 2015-01-30 2018-01-11 The Regents Of The University Of California Spinal subpial gene delivery system
US20180030096A1 (en) 2015-02-03 2018-02-01 University Of Florida Research Foundation, Inc. Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
EP4219728A3 (en) 2015-02-10 2023-08-23 Genzyme Corporation Enhanced delivery of viral particles to the striatum and cortex
WO2016137949A1 (en) 2015-02-23 2016-09-01 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
WO2016145217A1 (en) 2015-03-10 2016-09-15 The Trustees Of Columbia University In The City Of New York Recombinant glut1 adeno-associated viral vector constructs and related methods for restoring glut1 expression
WO2016154055A1 (en) 2015-03-20 2016-09-29 Bluebird Bio, Inc. Vector formulations
CA2979065A1 (en) 2015-03-24 2016-09-29 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
US20160319278A1 (en) 2015-04-03 2016-11-03 University Of Massachusetts Fully stabilized asymmetric sirna
US10081659B2 (en) 2015-04-06 2018-09-25 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Adeno-associated vectors for enhanced transduction and reduced immunogenicity
TWI707951B (en) 2015-04-08 2020-10-21 美商健臻公司 Production of oversized adeno-associated vectors
US10058624B2 (en) 2015-04-16 2018-08-28 Emory University Recombinant promoters and vectors for protein expression in liver and use thereof
CA3019315A1 (en) 2015-04-23 2016-10-27 University Of Massachusetts Modulation of aav vector transgene expression
WO2016172008A1 (en) 2015-04-24 2016-10-27 University Of Massachusetts Modified aav constructions and uses thereof
US20160346359A1 (en) 2015-05-01 2016-12-01 Spark Therapeutics, Inc. Adeno-associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease
WO2016179496A1 (en) 2015-05-07 2016-11-10 Massachusetts Eye And Ear Infirmary Methods of delivering an agent to the eye
JP6993234B2 (en) 2015-05-11 2022-01-13 アルキオーネ・ライフサイエンシズ・インコーポレイテッド Drug delivery system and method
US11447797B2 (en) 2015-05-12 2022-09-20 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service AAV with unique capsid protein VP1 and methods of using for treatment
US20170067028A1 (en) 2015-05-15 2017-03-09 Douglas J. Ballon Radiolabeling of adeno associated virus
WO2016191418A1 (en) 2015-05-26 2016-12-01 Salk Institute For Biological Studies Motor neuron-specific expression vectors
SG10202012832VA (en) 2015-05-28 2021-01-28 Univ Cornell Adeno-associated virus mediated delivery of c1ei as a therapy for angioedema
JP7011467B2 (en) 2015-05-29 2022-02-10 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Compositions and Methods for Degradation of Misfolded Proteins
WO2016196507A1 (en) 2015-05-29 2016-12-08 University Of Iowa Research Foundation Methods of delivery of transgenes for treating brain diseases
EP4378487A3 (en) 2015-06-23 2024-09-04 The Children's Hospital of Philadelphia Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
US11266748B2 (en) 2015-07-02 2022-03-08 University Of Florida Research Foundation, Incorporated Recombinant adeno-associated virus vectors to target medullary thyroid carcinoma
ES2895652T3 (en) 2015-07-07 2022-02-22 Inst Nat Sante Rech Med Methods and pharmaceutical compositions for expressing a polynucleotide of interest in the peripheral nervous system of a subject
US20170007669A1 (en) 2015-07-07 2017-01-12 Mayo Foundation For Medical Education And Research Peptide-mediated delivery of active agents across the blood-brain barrier
WO2017015102A1 (en) 2015-07-17 2017-01-26 The Trustees Of The University Of Pennsylvania Compositions and methods for achieving high levels of transduction in human liver cells
CA2988471A1 (en) 2015-07-28 2017-02-02 University Of Massachusetts Transgenic expression of dnase i in vivo delivered by an adeno-associated virus vector
CN108603235A (en) 2015-07-30 2018-09-28 马萨诸塞眼科耳科诊所 Ancestors' virus sequence and application thereof
US20190000940A1 (en) 2015-07-31 2019-01-03 Voyager Therapeutics, Inc. Compositions and methods for the treatment of aadc deficiency
CA2994552A1 (en) 2015-08-06 2017-02-09 The Trustees Of The University Of Pennsylvania Glucagon-like peptide 1 and use thereof in compositions for treating metabolic diseases
IL257939B2 (en) 2015-09-24 2023-03-01 Biomarin Pharm Inc Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same
SG10202107733QA (en) 2015-09-28 2021-09-29 Univ North Carolina Chapel Hill Methods and compositions for antibody-evading virus vectors
US10317329B2 (en) 2015-10-09 2019-06-11 Genzyme Corporation Early post-transfection isolation of cells (EPIC) for biologics production
US10123969B2 (en) 2015-10-15 2018-11-13 Wisconsin Alumni Research Foundation Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
WO2017070476A2 (en) 2015-10-22 2017-04-27 University Of Florida Research Foundation, Inc. Synthetic combinatorial aav3 capsid library
CA3002982A1 (en) 2015-10-22 2017-04-27 University Of Massachusetts Methods and compositions for treating metabolic imbalance in neurodegenerative disease
CA3002980A1 (en) 2015-10-22 2017-04-27 University Of Massachusetts Prostate-targeting adeno-associated virus serotype vectors
KR20180067684A (en) 2015-10-23 2018-06-20 유니버시티 오브 아이오와 리써치 파운데이션 Methods of treating neurodegenerative diseases using gene therapy to delay disease initiation and progression while providing cognitive protection
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
BR112018008407A2 (en) 2015-10-28 2018-11-27 Univ Pennsylvania intrathecal administration of adeno-associated viral vectors for gene therapy
CN108602884B (en) 2015-11-08 2024-06-25 豪夫迈·罗氏有限公司 Method for screening multispecific antibodies
WO2017083423A1 (en) 2015-11-10 2017-05-18 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating aav infection
US20170151416A1 (en) 2015-12-01 2017-06-01 Invivo Therapeutics Corporation Methods and Systems for Delivery of a Trail of a Therapeutic Substance into an Anatomical Space
US20190292561A1 (en) 2015-12-01 2019-09-26 Spark Therapeutics, Inc. Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use
US10406244B2 (en) 2015-12-02 2019-09-10 The Board Of Trustees Of The Leland Stanford Junior University AAV vectors with expanded packaging capacity
WO2017096164A1 (en) 2015-12-02 2017-06-08 The Board Of Trustees Of The Leland Stanford Junior University Novel recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism
EP3383896A1 (en) 2015-12-03 2018-10-10 Genethon Compositions and methods for improving viral vector efficiency
DK3387137T3 (en) 2015-12-11 2021-05-03 California Inst Of Techn TARGET TIPPID TIMES FOR MANAGING ADENO-ASSOCIATED VIRUSES (AAVs)
WO2017100704A1 (en) 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aavrh10
US11015173B2 (en) 2015-12-11 2021-05-25 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV1
WO2017100676A1 (en) 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav8
WO2017160360A2 (en) 2015-12-11 2017-09-21 The Trustees Of The University Of Pennsylvania Scalable purification method for aav9
CN108602859B (en) 2015-12-14 2023-05-26 北卡罗来纳大学教堂山分校 Modified capsid proteins to enhance parvoviral vector delivery
WO2017112948A1 (en) 2015-12-24 2017-06-29 University Of Florida Research Foundation, Inc. Improved aav production using suspension adapted cells
CA3011459A1 (en) 2016-01-13 2017-07-20 Merial, Inc. Recombinant aav vectors expressing osteoprotective genes, including has2 and lubricin, useful in the treatment of osteoarthritis and related joint conditions in mammals
JP6924441B2 (en) 2016-01-15 2021-08-25 学校法人自治医科大学 Adeno-associated virus virions for the treatment of epilepsy
US11826433B2 (en) 2016-02-02 2023-11-28 University Of Massachusetts Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system
ES2962860T3 (en) 2016-02-05 2024-03-21 Univ Emory Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
JP6947739B2 (en) 2016-02-16 2021-10-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Newly recombinant adeno-associated virus capsid resistant to existing human neutralizing antibodies
US20190071681A1 (en) 2016-02-26 2019-03-07 University Of Florida Research Foundation, Incorporated Aav heparin mutants that display significantly improved eye and brain transduction
WO2017151884A1 (en) 2016-03-02 2017-09-08 The Children's Hospital Of Philadelphia Therapy for frontotemporal dementia
US11066679B2 (en) 2016-03-03 2021-07-20 University Of Massachusetts Closed-ended linear duplex DNA for non-viral gene transfer
CA3016985C (en) 2016-03-07 2023-07-04 University Of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
EP3433266A4 (en) 2016-03-23 2019-11-06 The Regents of the University of California Methods of treating mitochondrial disorders
WO2017165859A1 (en) 2016-03-24 2017-09-28 Research Institute At Nationwide Children's Hospital Modified viral capsid proteins
DK3436593T3 (en) 2016-03-28 2023-02-20 Ultragenyx Pharmaceutical Inc METHODS FOR HEAT INACTIVATION OF ADENOVIRUS
WO2017172733A1 (en) 2016-03-28 2017-10-05 The Regents Of The University Of California Anti-ryk antibodies and methods of using the same
CA3019126A1 (en) 2016-03-30 2017-10-05 Spark Therapeutics, Inc. Cell line for recombinant protein and/or viral vector production
CA3019133A1 (en) 2016-03-31 2017-10-05 Spark Therapeutics, Inc. Column-based fully scalable raav manufacturing process
US11091776B2 (en) 2016-04-15 2021-08-17 The Trustees Of The University Of Pennsylvania AAV8 mutant capsids and compositions containing same
WO2017181162A1 (en) 2016-04-16 2017-10-19 University Of Florida Research Foundation, Incorporated Methods of enhancing biological potency of baculovirus system-produced recombinant adeno-associated virus
WO2017184879A1 (en) 2016-04-21 2017-10-26 Virovek, Inc Aav production in insect cells, methods and compositions therefor
EP3235516B1 (en) 2016-04-22 2019-06-26 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin Regulatable adeno-associated virus (aav) vector
WO2017190031A1 (en) 2016-04-28 2017-11-02 Indiana University Research And Technology Corporation Methods and compositions for resolving components of a virus preparation
AU2017261249B2 (en) 2016-05-03 2021-05-06 Children's Medical Research Institute Adeno-associated virus polynucleotides, polypeptides and virions
WO2017192750A1 (en) 2016-05-04 2017-11-09 Oregon Health & Science University Recombinant adeno-associated viral vectors
CA3059891A1 (en) 2017-04-14 2018-10-18 National Taiwan University Gene therapy for aadc deficiency
JOP20190269A1 (en) 2017-06-15 2019-11-20 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
KR20210019996A (en) 2018-05-15 2021-02-23 보이저 테라퓨틱스, 인크. Composition and method for the treatment of Parkinson's disease

Also Published As

Publication number Publication date
RU2716991C2 (en) 2020-03-17
CA2966620A1 (en) 2016-05-12
JP6878370B2 (en) 2021-05-26
JP2017535291A (en) 2017-11-30
JP2018198622A (en) 2018-12-20
JP6401871B2 (en) 2018-10-10
US20190008933A1 (en) 2019-01-10
KR20170096998A (en) 2017-08-25
AU2015343037A1 (en) 2017-05-11
JP2021106619A (en) 2021-07-29
IL280530A (en) 2021-03-01
US20190008931A1 (en) 2019-01-10
US11027000B2 (en) 2021-06-08
EP3215191B1 (en) 2024-08-14
AU2019202498A1 (en) 2019-05-02
RU2020109343A (en) 2020-03-17
IL251787A0 (en) 2017-06-29
AU2015343037B2 (en) 2019-01-17
WO2016073693A3 (en) 2016-06-30
HK1243922A1 (en) 2018-07-27
US20190008932A1 (en) 2019-01-10
RU2017115477A3 (en) 2019-03-26
AU2019202498B2 (en) 2021-04-01
IL251787B (en) 2021-02-28
US10335466B2 (en) 2019-07-02
WO2016073693A2 (en) 2016-05-12
CN107106689A (en) 2017-08-29
US20190358306A1 (en) 2019-11-28
SG10202007103TA (en) 2020-09-29
US11975056B2 (en) 2024-05-07
EP3215191A2 (en) 2017-09-13
EP3215191A4 (en) 2018-08-01
US20210338786A1 (en) 2021-11-04
MX2017005834A (en) 2017-11-17
RU2017115477A (en) 2018-11-09
US20170333538A1 (en) 2017-11-23
JP2019010110A (en) 2019-01-24
CN112553229A (en) 2021-03-26
BR112017009497A2 (en) 2018-02-06

Similar Documents

Publication Publication Date Title
IL280530A (en) Aadc polynucleotides for the treatment of parkinson's disease
IL270821A (en) Aadc polynucleotides for the treatment of parkinson’s disease
IL285722A (en) Methods for treating alzheimer's disease
IL247085B (en) Methods of treating alzheimer's disease
PL2968218T3 (en) Combination for the treatment of parkinson's disease
ZA201605341B (en) Methods of treating alzheimer's disease
IL263188B (en) Treatment for parkinson's disease
IL248592A0 (en) Treatment of crohn's disease with delayed-release 6-mercaptopurine
HUE039750T2 (en) 6-hydroxybuspirone for use in the treatment of movement disorders
EP3538095A4 (en) Methods for treating parkinson's disease
HK1244449A1 (en) Methods for treating psychosis associated with parkinson's disease
HK1245081A1 (en) Methods for treating alzheimer's disease
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
ZA201807944B (en) Treatment for parkinson's disease
GB201518052D0 (en) Parkinson's disease treatment
GB201504144D0 (en) Treatment of Parkinson's disease
GB201610205D0 (en) Therapies for parkinson's disease
GB201602011D0 (en) Treating skin disorders
GB201414038D0 (en) Alzheimer's disease
GB201406225D0 (en) Treatment for respiratory disease